Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine loading-dose pharmacokinetic study in adult patients with nontuberculous mycobacterial disease
NL-OMON50996Phase 2Completed
- Sponsor
- Ziekenhuisapotheek
- Start
- Apr 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of clofazimine in nontuberculous mycobacteria infection, nontuberculous mycobacterial lung disease, sponsored by Ziekenhuisapotheek. Started Apr 2022; status: completed.
02
Drugs
clofazimine
03
Conditions
nontuberculous mycobacteria infectionnontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NL-OMON50996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50996.